No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 19
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for GRI Bio, Inc. (GRI) stock was $1.91 as of Oct 6, 2026, 10:27 AM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months -96.4% · 3-year avg -97.0%/yr · 5-year avg -95.4%/yr
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Biotechnology · La Jolla, CA
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.84
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.91
vs Estimate
$-1.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GRI | $4.18M | $1.91 | +0.00% | -96.44% | -95.39% | N/A | N/A |
| 2AIDX | $4.20M | $0.34 | -2.67% | N/A | N/A | N/A | vs GRI |
| 3APVO | $4.06M | $1.86 | +3.10% | -92.21% | -95.30% | -80.35% | vs GRI |
| 4ERNA | $4.04M | $2.48 | -8.33% | -90.95% | -86.83% | -65.14% | vs GRI |
| 5CLGN | $4.43M | $3.42 | +0.29% | -85.66% | -53.69% | N/A | vs GRI |
| 6DRMA | $4.50M | $1.12 | +0.90% | -77.00% | -83.90% | N/A | vs GRI |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$18.50
+868.6% upside
Low
$10.00
Current
$1.91
High
$27.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.93 | $-0.84 | $-0.75 | 2 |
| Quarter ending Dec 2026 | $-0.90 | $-0.82 | $-0.74 | 2 |
| Quarter ending Mar 2027 | $-0.98 | $-0.98 | $-0.98 | 1 |
| Quarter ending Jun 2027 | $-0.96 | $-0.96 | $-0.96 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.29 | $-3.90 | $-3.49 | 2 |
| FY 2027 | $-3.79 | $-2.00 | $-0.21 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
